The Impact of Antimicrobial Therapy Duration in the Treatment of Prosthetic Joint Infections Depending on Surgical Strategies: A Systematic Review and Meta-analysis.
DAIR
antibiotic therapy duration
meta-analysis
prosthetic joint infection
systematic review
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
15
03
2023
accepted:
05
05
2023
medline:
2
6
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
epublish
Résumé
The aim of this systematic review was to address the question if short antibiotic treatment (SAT; at least 4 but <12 weeks) versus long antibiotic treatment (LAT) affects outcomes in prosthetic joint infections (PJIs). Database research (Medline, Embase, Web of Science, Scopus, Cochrane) retrieved 3740 articles, of which 10 studies were included in the analysis. Compared to LAT, 11% lower odds of treatment failure in the SAT group were found, although the difference was not statistically significant (pooled odds ratio, 0.89 [95% confidence interval, .53-1.50]). No difference in treatment failure was found between SAT and LAT once stratified by type of surgery, studies conducted in the United States versus Europe, study design, and follow-up. There is still no conclusive evidence that antibiotic treatment of PJIs for 12 weeks or longer is associated with better outcomes, irrespective of the type of surgical procedure. Most recent, high-quality studies tend to favor longer antibiotic courses, making them preferable in most situations.
Identifiants
pubmed: 37265666
doi: 10.1093/ofid/ofad246
pii: ofad246
pmc: PMC10230567
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
ofad246Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors: No reported conflicts of interest.
Références
EClinicalMedicine. 2021 Nov 06;42:101192
pubmed: 34805813
J Clin Med. 2019 Feb 09;8(2):
pubmed: 30744128
J Bone Joint Surg Am. 2007 Jun;89(6):1227-31
pubmed: 17545425
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
J Infect. 2010 Jul;61(2):125-32
pubmed: 20540962
Ann Rheum Dis. 2014 Jul;73(7):1323-30
pubmed: 24553908
Bone Joint J. 2020 Jun;102-B(6_Supple_A):3-9
pubmed: 32475278
JAMA. 1998 May 20;279(19):1537-41
pubmed: 9605897
J Antimicrob Chemother. 2019 Sep 1;74(9):2507-2516
pubmed: 31050758
J Arthroplasty. 2022 Aug;37(8S):S989-S996
pubmed: 35074446
Pharmacoepidemiol Drug Saf. 2008 May;17(5):523-32
pubmed: 18215001
Ann Intern Med. 2019 Aug 6;171(3):210-211
pubmed: 31284302
N Engl J Med. 2004 Oct 14;351(16):1645-54
pubmed: 15483283
J Antimicrob Chemother. 2014 Sep;69 Suppl 1:i37-40
pubmed: 25135088
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Bone Joint J. 2021 Jan;103-B(1):18-25
pubmed: 33380199
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
JBJS Rev. 2022 Jan 12;10(1):
pubmed: 35020709
J Arthroplasty. 2018 May;33(5):1309-1314.e2
pubmed: 29551303
Arthroplast Today. 2017 Jun 20;3(2):137-140
pubmed: 28695187
J Antimicrob Chemother. 2004 Feb;53(2):127-9
pubmed: 14688050
Int J Antimicrob Agents. 2016 Sep;48(3):310-6
pubmed: 27524103
J Gastrointest Surg. 2013 Jun;17(6):1170-1
pubmed: 23233271
Int J Epidemiol. 2008 Oct;37(5):1148-57
pubmed: 18424475
Clin Microbiol Infect. 2012 Nov;18(11):1143-8
pubmed: 22070556
Int J Infect Dis. 2017 Oct;63:37-42
pubmed: 28804007
J Arthroplasty. 2020 Apr;35(4):1154-1160
pubmed: 31955984
J Antimicrob Chemother. 2019 Aug 1;74(8):2394-2399
pubmed: 31106353
N Engl J Med. 2021 May 27;384(21):1991-2001
pubmed: 34042388
BMJ Open. 2015 Dec 07;5(12):e009495
pubmed: 26644124
Int J Antimicrob Agents. 2005 Aug;26(2):106-13
pubmed: 16009535
Trials. 2023 Feb 18;24(1):117
pubmed: 36803837
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Hip Int. 2021 May;31(3):286-294
pubmed: 32459114